https://www.consultantlive.com/view/zilebesiran-rnai-for-hypertension-heads-to-phase-3-cardiovascular-outcomes-trial
Zilebesiran, RNAi for Hypertension, Heads to Phase 3 Cardiovascular Outcomes Trial
Alnylam Pharmaceuticals debuts phase 2 KARDIA-3 data at ESC 2025 and advances zilebesiran into a phase 3 outcomes trial.
zilebesiranrnaihypertensionheads
https://druganalyst.com/Roche/zilebesiran
zilebesiran (zilebesiran) - Roche Sales History and Forecasts - DRUGANALYST
sales historyzilebesiranrocheforecasts